All News

FDA has been rolling out new guidelines for using interactive media in recent months. The new guidances clarify some murky areas, but may not make online communications any easier.

The hemophilia treatment landscape is to undergo a radical shift away from established short-acting therapies, beginning with the launch of Biogen Idec’s long-acting rFVIII and rFIX products this year, according to research and consulting firm GlobalData.

Prescriptions to manage diabetes in primary care in the UK cost the NHS an average of £2.2 million ($3.7 m) every day in 2013-14, according to a report from the Health and Social Care Information Centre (HSCIC).

According to the Tufts Center for the Study of Drug Development R&D Management Report, more than half of all new drugs approved in the US between 2000 and 2011 were developed by companies that collaborated in one form or another with other entities.

By the middle of 2015, global healthcare giant Baxter International Inc. is expected to officially split off its BioScience business, establishing the unit as an independent, innovation-focused biotechnology company.

The pharma, medical and biotech (PMB) sector, driven by the Novartis’s £8.6bn acquisition of GlaxoSmithKline’s oncology division, was the most active industry in UK M&A in H1 2014, with a 26.9% market share (£10.1bn), according to Mergermarket’s latest deal round-up.

The European Union’s decentralized procedure is to be used by international regulatory agencies as a model for facilitating generic-drug application assessments, as part of the International Generic Drug Regulations Pilot (IGDRP) project.

PharmaChk, a portable anticounterfeiting device, has received a $2 million transition-to-scale grant from Saving Lives at Birth: A Grand Challenge for Development.

Mexico’s pharmaceutical industry will be worth approximately US$22.5 billion by 2020, according to research and consulting firm GlobalData.

In this Applied Clinical Trials article, Kadmon CEO Dr. Sam Waksal talks about the importance of imagination for innovation, current business risks in biopharma, and applying understanding to the concept of Big Data.

Medtech employment remained steady in last year with most medical device makers experiencing an increase in their workforce, according to a new jobs report published by EP Vantage.

With the recent approval of Jardiance in the US, Eli Lilly and partner Boehringer Ingelheim (BI) “have taken another step towards owning the most comprehensive diabetes portfolio in the industry”, according to research and consulting firm GlobalData.

The European Medicines Agency (EMA) has released a consultation on good genomics biomarker practices.

Novartis reports that its KAE609 is the first antimalarial drug candidate with a novel mechanism of action to achieve positive clinical proof-of-concept in over 20 years.

In the media world, it’s easy to see when a market is really taking off - someone starts a magazine or a website about it.

FDA has announced it is taking steps to ensure that certain diagnostic tests are accurate, consistent and reliable.

As Europe departs for its annual holiday-sacrosanct, even amid the continuing economic woes, the multiple crises in the Middle East, and the dark mysteries of Russia’s intentions in its former satellites-the question remains unresolved as to what to expect from the new European Parliament in the new term.

The European Medicines Agency (EMA) has released the second module of a new overarching guideline on influenza vaccines for a six-month public consultation.

The Joint United Nations Programme on HIV/AIDS (UNAIDS) and the African Society for Laboratory Medicine (ASLM) have joined with a number of global partners to launch the Diagnostics Access Initiative.

A new report from Frost & Sullivan forecasts “robust demand” for HCV antivirals, with several strong competitors “maneuvering aggressively” to narrow the market gap by introducing a treatment that can outdo Gilead’s Sovaldi.

GSK announced that it has submitted a regulatory filing to the European Medicines Agency (EMA) for its malaria vaccine candidate, RTS,S.

Over the years, healthcare professionals have needed to adapt to a more highly informed patient population due to improvements in the availability of accessible healthcare information through the internet.

PCMA represents several American managed care entities and has been an active participant in the national debate over the issue of high priced biotech Rx drugs.

The launch of several drugs with “extraordinary blockbuster potential” will more than triple the acute coronary syndrome (ACS) treatment market, from $12.3 billion in 2013 to $43.4 billion by 2023, according to research and consulting firm GlobalData.

With all of the buzz and excitement around risk-based monitoring (RBM), one might expect that the broad adoption of this emerging clinical research paradigm is well underway.

Sanofi Pasteur, the vaccines division of Sanofi, reports that results of an efficacy study is a step closer to making dengue the next vaccine-preventable disease.

After months of speculation about prospects for biosimilar development in the U.S., Novartis announced July 24 that FDA has accepted Sandoz’ biologics license application (BLA) for a similar version of Amgen’s Neupogen (filgrastim).

The European Union’s struggle to bring its data protection rules into the 21st century continues-haltingly-as the EU itself enters its new era, with a new European Parliament, a new President-designate of the European Commission, and a new European Commission due to take office in November.